7:08AM Seattle Genetics: Trading of Seattle Genetics common stock halted ahead of FDA meeting (SGEN) 20.33 : The U.S. FDA and Oncologic Drugs Advisory Committee is meeting today to discuss the co's Biologics License Applications for ADCETRIS. ODAC will review the BLA for the treatment of relapsed or refractory Hodgkin lymphoma during the morning session and the BLA for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma during the afternoon session. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of Hodgkin lymphoma and ALCL.
Market Data 
Markets 
AI
